In a report released today, Marc Frahm from TD Cowen maintained a Buy rating on Adaptimmune Therapeutics (ADAP – Research Report). The company’s shares opened today at $1.19.
According to TipRanks, Frahm is a 5-star analyst with an average return of 27.0% and a 50.29% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Incyte, Theravance Biopharma, and Adaptimmune Therapeutics.
Adaptimmune Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $3.75.
The company has a one-year high of $2.05 and a one-year low of $0.42. Currently, Adaptimmune Therapeutics has an average volume of 1.48M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Adaptimmune Therapeutics (ADAP) Company Description:
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
